Innoviva, Inc. operates as a biopharmaceutical and healthcare royalty management company based in Burlingame, California. The company's core business revolves around managing a lucrative royalty portfolio of respiratory assets partnered with Glaxo Group Limited (GSK), which includes once-daily combination medicines like RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. Beyond its royalty streams, Innoviva has expanded its operational footprint into critical care and infectious diseases, marketing proprietary products such as GIAPREZA for distributive shock, XACDURO for bacterial pneumonia, and XERAVA for complicated intra-abdominal infections. The company also holds strategic healthcare investments, including significant stakes in biopharmaceutical ventures like Armata Pharmaceuticals. Originally founded in 1996 as Advanced Medicine, Inc. and later operating as Theravance, Inc., the company spun off its research arm in 2014 and rebranded as Innoviva in 2016 to focus on its royalty and healthcare investment platform.
